中国医学创新2024，Vol.21Issue(1)：9-13,5.DOI:10.3969/j.issn.1674-4985.2024.01.003
罗沙司他治疗慢性肾脏病伴肾性贫血患者的效果及安全性研究
Study on the Efficacy and Safety of Roxadustat in the Treatment of Patients with Chronic Kidney Disease Complicated with Renal Anemia
摘要
Abstract
Objective:To investigate the clinical effect and safety of Roxadustat in the treatment of patients with chronic kidney disease complicated with renal anemia.Method:A total of 96 patients with chronic kidney disease complicated with renal anemia admitted to Changzhou No.7 People's Hospital from January 2021 to June 2022 were selected and divided into two groups according to computer random number method,with 48 cases in each group.The control group was given routine clinical treatment,and the study group was given Roxadustat treatment on the basis of the control group.The efficacy,levels of inflammatory factors,anemia-related indexes and drug safety were compared between the two groups.Result:The total effective rate of the study group was significantly higher than that of the control group(P＜0.05).Before treatment,there were no significant differences in the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C reactive protein(hs-CRP)and procalcitonin(PCT)between the two groups(P＞0.05).After treatment,the levels of TNF-α,IL-6,hs-CRP and PCT in both groups were lower than those before treatment,and those in the study group were significantly lower than those in the control group(P＜0.05).Before treatment,there were no significant differences in the levels of hemoglobin(Hb),red blood cell count(RBC),serum ferritin(SF)and hepcidin(Hepc)levels between the two groups(P＞0.05).After treatment,the levels of Hb,RBC and SF in both groups were significantly higher than those before treatment,and those in the study group were significantly higher than those in the control group(P＜0.05).The levels of Hepc in the two groups after treatment were significantly lower than those before treatment,and that in the study group was significantly lower than that in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:Roxadustat is used in the clinical treatment of patients with chronic kidney disease complicated with renal anemia,the inflammation and anemia situation of patients have been significantly improved,and the clinical efficacy has been significantly improved,and the drug is relatively safe and controllable.关键词
慢性肾脏病/肾性贫血/罗沙司他/炎症反应Key words
Chronic kidney disease/Renal anemia/Roxadustat/Inflammatory reaction引用本文复制引用
赵乐,刘祥英..罗沙司他治疗慢性肾脏病伴肾性贫血患者的效果及安全性研究[J].中国医学创新,2024,21(1):9-13,5.基金项目
常州市卫健委科技项目(ZD202229) （ZD202229）
